Upgrade to SI Premium - Free Trial

TD Cowen Reiterates Buy Rating on Guardant Health (GH), $245M Patent Judgment Risks Seen as Managable

August 25, 2026 7:34 AM
TD Cowen analyst Dan Brennan reiterated a Buy rating and $210.00 price target on Guardant Health (NASDAQ: GH).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments